Venetoclax not recommended by NICE in round two

The National Institute for Health and Care Excellence (NICE) has issued a second Appraisal Consultation Document (ACD) not recommending the routine National Health Service use of Venclexta (venetoclax) for patients with certain types of difficult-to-treat relapsed and refractory chronic lymphocytic leukemia (CLL). This follows a first Appraisal consultation document issued in February 2017.

Nice report